ERBB2 and breast carcinoma: Indeed, preliminary clinical data indicate that neratinib remains clinically active in the treatment of HER2+ breast cancers that have progressed on prior lapatinib-based therapy (Chow L, et al. Efficacy and safety of neratinib (HKI-272) in combination with paclitaxel in HER2+ metastatic breast cancer.